Perflutren for Carotid Artery Disease

This trial aims to test a new method for assessing pressure differences in the carotid artery, which can help determine the risk level of plaque buildup. The treatment uses an ultrasound contrast agent called Perflutren to measure these differences non-surgically. Individuals with atherosclerosis who plan to undergo a procedure to remove plaque from their carotid artery might be suitable candidates for this trial. As a Phase 4 trial, this research involves an FDA-approved treatment and seeks to understand its benefits for a broader range of patients.

The trial information does not specify if you need to stop taking your current medications. However, if you have recently received any contrast medium for imaging tests, you may need to wait 24 hours before participating.

Research has shown that perflutren is generally safe for people. Previous studies found that this ultrasound contrast agent is well-tolerated. It is used in a simple procedure to create images of carotid artery plaques, which are buildups in the artery that can cause blockages.

Contrast-enhanced ultrasound, which uses perflutren, is considered a safe way to check these plaques. This method is helpful because it doesn't involve surgery or other invasive procedures.

Most treatments for carotid artery disease focus on reducing plaque buildup or managing symptoms through medications like statins and antiplatelet agents. But Perflutren works differently, as it is used as a contrast agent in ultrasound imaging to enhance the assessment of plaque characteristics. Researchers are excited about this treatment because it allows for detailed 3D imaging of the plaque, which could help in accurately evaluating its stability and potential risk. This innovative approach might lead to more precise and personalized treatment plans for patients.

Studies have shown that perflutren, when used in contrast-enhanced ultrasound, helps detect changes in the carotid arteries related to heart disease. Research indicates that new blood vessels forming within plaque (a build-up in the arteries) can predict future heart problems. In patients with carotid atherosclerosis (a type of artery disease), these ultrasound signals are stronger and relate to thicker artery walls. The trial will use perflutren in the "Carotid SHAPE estimation" arm to assess its effectiveness in identifying risky plaques that might lead to heart issues. Overall evidence supports its effectiveness in assessing and managing carotid artery disease.¹⁶⁷⁸⁹